Ovid Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference
September 07, 2022 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives...
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
August 09, 2022 08:00 ET
|
Ovid Therapeutics Inc.
Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the second half of 2022 Presented preclinical data...
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference
June 06, 2022 08:00 ET
|
Ovid Therapeutics Inc.
OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate OV329 has the potential for an improved...
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
May 10, 2022 08:00 ET
|
Ovid Therapeutics Inc.
Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in the fourth quarter of 2022Data supporting...
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 08, 2022 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies...
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
March 15, 2022 08:00 ET
|
Ovid Therapeutics Inc.
Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by 20% and increase operational...
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference
March 04, 2022 08:00 ET
|
Ovid Therapeutics Inc.
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people affected by...
Healx and Ovid Therapeutics to Enter Strategic Partnership
February 08, 2022 08:00 ET
|
Ovid Therapeutics Inc.
– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and CAMBRIDGE, United Kingdom, Feb. 08, 2022 (GLOBE...
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
January 03, 2022 06:30 ET
|
Ovid Therapeutics Inc.
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapiesCollaboration with Dr. Stephen Moss,...
Ovid Therapeutics Reports Third Quarter 2021 Business Update, Corporate Highlights and Financial Results
November 10, 2021 08:30 ET
|
Ovid Therapeutics Inc.
Ovid is implementing its business development program which intends to secure a series of opportunities that complement and enhance its pipeline of precision and small-molecule CNS medicinesA...